Extract
The fraction of exhaled nitric oxide (FeNO) is a biomarker for type 2 asthma, reflecting the degree of local pulmonary inflammation linked to immune pathways including interleukin (IL) 13 [1]. In clinical practice, FeNO is a reliable marker for inhaled corticosteroid (ICS) responsiveness [2] and the efficacy of biological therapies such as those targeting IL4/IL13 pathways [3, 4], as well as the detection of steroid nonadherence or resistance in severe asthma [2]. The prospective Severe Asthma Registry of the German Asthma Net (GAN) enrols patients with severe asthma for in-depth assessment of phenotypes, underlying mechanisms, and therapeutic strategies; GAN has been approved by respective ethics committees, with all included patients having signed informed consent [5]. Prior studies of FeNO either included patients with asthma of any severity [6] or did not involve a comprehensive analysis in a large cohort [7]. We therefore used cross-sectional data from GAN to determine the correlation of FeNO with epidemiologic, laboratory, clinical, lung function, or quality of life parameters and the need for oral corticosteroid (OCS) maintenance therapy in a carefully selected severe asthma cohort to better characterise the severe asthma subtype with high FeNO values.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Christina Bal has nothing to disclose.
Conflict of interest: Marco Idzko reports lectures fees from AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, GSK, Menarini, MSD, Novartis, Roche, Sanofi, Thermofischer and advisory board fees from Alk-Pharma, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL-Behring, GSK, Novartis, and Sanofi, all outside the submitted work.
Conflict of interest: Sabina Škrgat reports fees from Boehringer Ingelheim, GSK, Novartis, AstraZeneca, and Chiesi, all outside the submitted work.
Conflict of interest: Andrea Koch reports personal fees from AstraZeneca, Novartis, Sanofi, and Boehringer Ingelheim, all outside the submitted work.
Conflict of interest: Katrin Milger reports personal fees from AstraZeneca, GSK, Novartis, and Sanofi, all outside the submitted work.
Conflict of interest: Christian Schulz received personal fees from Boehringer Ingelheim, Novartis, and AstraZeneca, all outside the submitted work.
Conflict of interest: Sonja Zehetmayer has nothing to disclose.
Conflict of interest: Eckard Hamelmann is funded by the German Ministry of Education and Research (BMBF) (CHAMP, Project Number: 01GL1742D) for characterisation of children and adolescents with severe asthma. He reports personal fees from ALK, Boehringer Ingelheim, GSK, Leti Pharma, Novartis, Nutricia, Sanofi, and Stallergenes all outside the submitted work.
Conflict of interest: Roland Buhl reports grants to Mainz University and personal fees from Boehringer Ingelheim, GSK, Novartis, and Roche, as well as personal fees from AstraZeneca, Chiesi, Cipla, Sanofi, and Teva, all outside the submitted work.
Conflict of interest: Stephanie Korn reports grants to Mainz University and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Roche, and Sanofi, as well as personal fees from AstraZeneca, GSK, Novartis, Sanofi, and Teva, all outside the submitted work.
- Received January 24, 2021.
- Accepted February 9, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
